Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Public ClinicalTrials.gov record NCT04102579. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
Study identification
- NCT ID
- NCT04102579
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 128 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2019 (Actual)
- Primary completion
- Oct 15, 2021 (Actual)
- Completion
- Oct 26, 2021 (Actual)
- Last update posted
- Oct 11, 2023
2019 – 2021
United States locations
- U.S. sites
- 42
- U.S. states
- 28
- U.S. cities
- 40
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Birmingham | Alabama | 35233 | — |
| Neurocrine Clinical Site | Little Rock | Arkansas | 72205 | — |
| Neurocrine Clinical Site | La Jolla | California | 92037 | — |
| Neurocrine Clinical Site | Sacramento | California | 95817 | — |
| Neurocrine Clinical Site | Aurora | Colorado | 80045 | — |
| Neurocrine Clinical Site | Englewood | Colorado | 80113 | — |
| Neurocrine Clinical Site | Washington D.C. | District of Columbia | 20007 | — |
| Neurocrine Clinical Site | Gainesville | Florida | 32608 | — |
| Neurocrine Clinical Site | Miami | Florida | 33136 | — |
| Neurocrine Clinical Site | Atlanta | Georgia | 30329 | — |
| Neurocrine Clinical Site | Chicago | Illinois | 60611 | — |
| Neurocrine Clinical Site | Chicago | Illinois | 60612 | — |
| Neurocrine Clinical Site | Indianapolis | Indiana | 46202 | — |
| Neurocrine Clinical Site | Iowa City | Iowa | 52242 | — |
| Neurocrine Clinical Site | Kansas City | Kansas | 66160 | — |
| Neurocrine Clinical Site | Wichita | Kansas | 67226 | — |
| Neurocrine Clinical Site | Louisville | Kentucky | 40202 | — |
| Neurocrine Clinical Site | New Orleans | Louisiana | 70121 | — |
| Neurocrine Clinical Site | Boston | Massachusetts | 02118 | — |
| Neurocrine Clinical Site | Boston | Massachusetts | 02215 | — |
| Neurocrine Clinical Site | Charlestown | Massachusetts | 02129 | — |
| Neurocrine Clinical Site | Ann Arbor | Michigan | 48109 | — |
| Neurocrine Clinical Site | West Bloomfield | Michigan | 48322 | — |
| Neurocrine Clinical Site | Omaha | Nebraska | 68198 | — |
| Neurocrine Clinical Site | Rochester | New York | 14618 | — |
| Neurocrine Clinical Site | Williamsville | New York | 14221 | — |
| Neurocrine Clinical Site | Durham | North Carolina | 27705 | — |
| Neurocrine Clinical Site | Fargo | North Dakota | 58103 | — |
| Neurocrine Clinical Site | Cleveland | Ohio | 44195 | — |
| Neurocrine Clinical Site | Columbus | Ohio | 43210 | — |
| Neurocrine Clinical Site | Toledo | Ohio | 43614 | — |
| Neurocrine Clinical Site | Pittsburgh | Pennsylvania | 15213 | — |
| Neurocrine Clinical Site | Charleston | South Carolina | 29425 | — |
| Neurocrine Clinical Site | Columbia | South Carolina | 29203 | — |
| Neurocrine Clinical Site | Greenville | South Carolina | 29615 | — |
| Neurocrine Clinical Site | Nashville | Tennessee | 37212 | — |
| Neurocrine Clinical Site | Houston | Texas | 77054 | — |
| Neurocrine Clinical Site | Salt Lake City | Utah | 84108 | — |
| Neurocrine Clinical Site | Burlington | Vermont | 05401 | — |
| Neurocrine Clinical Site | Charlottesville | Virginia | 22908 | — |
| Neurocrine Clinical Site | Seattle | Washington | 98195 | — |
| Neurocrine Clinical Site | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04102579, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2023 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04102579 live on ClinicalTrials.gov.